Zoetis' Q4 2023 earnings showcased strong performance with revenue reaching $2.2 billion, an 8% increase year-over-year. Net income grew by 14% to $525 million, with adjusted EPS at $1.24. The company's growth was fueled by companion animal products, particularly monoclonal antibody products and dermatology portfolios.
Revenue increased by 8% to $2.2 billion.
Net income rose by 14% to $525 million, or $1.14 per diluted share.
Adjusted net income was $569 million, or $1.24 per diluted share.
Companion animal products drove growth, especially monoclonal antibody products and dermatology portfolios.
Zoetis is providing full year 2024 guidance, which includes revenue between $9.075 billion to $9.225 billion (operational growth of 7% to 9%), and adjusted diluted EPS between $5.74 to $5.84.
Visualization of income flow from segment revenue to net income